GH Research PLC (GHRS)

Name: GH Research PLC (GHRS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: GH Research PLC (GHRS)

Stock Card

$27.12

$-0.82 (-2.93%)

As on 31-Aug-2026 12:34EDT

Market cap

$1,918 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

5.5

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

GH Research PLC (GHRS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 26.68 High: 27.89

52 Week Range

Low: 11.83 High: 31.44

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-12
Debt to Equity

0
Book Value

$--
EPS

$-1
Face value

--
Shares outstanding

68,642,287

5 Years Aggregate

CFO

$-76.19 Mln

EBITDA

$-94.47 Mln

Net Profit

$-52.69 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
GH Research PLC (GHRS)	113.5	-4.4	13.0	100.9	36.3	4.9	--
BSE Sensex	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022
GH Research PLC (GHRS)	81.4	-40.3	-58.3
S&P Small-Cap 600	4.0	13.9	-17.4
BSE Sensex	9.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
GH Research PLC (GHRS)	27.1	1,917.9	0.0	-62.3	--	-19.5	--	5.5
Alkermes (ALKS)	47.4	7,953.7	1,667.7	66.1	9.4	3.6	128.1	4.5
Iterum Therapeutics PLC (ITRM)	0.1	1.6	0.4	-27.0	-6,253.1	--	--	0.4
Prothena (PRTA)	9.2	479.0	54.5	-44.0	-80.0	-15.5	--	1.6

Shareholding Pattern

View Details

About GH Research PLC (GHRS)

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate... that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Read more

Co-Founder & Non-Executive Chairman of the Board

Mr. Florian Schonharting M.Sc. (Econ)
Co-Founder & Non-Executive Chairman of the Board

Mr. Florian Schonharting M.Sc. (Econ)
Headquarters

Dublin
Website

https://www.ghres.com

FAQs for GH Research PLC (GHRS)

What is the current share price of GH Research PLC (GHRS) Today?

The share price of GH Research PLC (GHRS) is $27.12 (NASDAQ) as of 31-Aug-2026 12:34 EDT. GH Research PLC (GHRS) has given a return of 36.34% in the last 3 years.

What is the current PB & PE ratio of GH Research PLC (GHRS)?

Since, TTM earnings of GH Research PLC (GHRS) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-16.32	2.82
2024	-9.35	2.04
2023	-8.48	1.38
2022	-22.52	2.02
2021	-131.89	4.38

What is the 52 Week High and Low of GH Research PLC (GHRS)?

The 52-week high and low of GH Research PLC (GHRS) are Rs 31.44 and Rs 11.83 as of 31-Aug-2026.

What is the market cap of GH Research PLC (GHRS)?

GH Research PLC (GHRS) has a market capitalisation of $ 1,918 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in GH Research PLC (GHRS)?

Before investing in GH Research PLC (GHRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.